Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Most people who switched said price impacted the decision66% cited the cost of name brand drugs as the primary reason for switching, while 34% cited problems with insurance coverage
Discussion Significant weight reduction ability of semaglutide has been demonstrated in various phase-3 clinical trials, for which recently semaglutide became the first long-acting GLP-1 receptor agonist to be approved by the United States Food and Drug Administration for management of obesity
varies by tier
Other potential concerns associated with tirzepatide: Birth control interactions: Tirzepatide may reduce the effectiveness of oral hormonal birth control, such as desogestrel, ethinyl estradiol, and levonorgestrel, so it is recommended to switch to non-oral contraceptives before starting tirzepatide
